Evidence map›Paper›PMID 24242015›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

T11TS inhibits glioma angiogenesis by modulation of MMPs, TIMPs, with related integrin αv and TGF-β1 expressions.

Manoj Kumar Singh, Debanjan Bhattacharya, Suhnrita Chaudhuri, Sagar Acharya, Pankaj Kumar, Pranjal Santra, Anjan Kumar Basu, Swapna Chaudhuri

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. PinX1 inhibits cell proliferation, migration and invasion in glioma cells.Medical oncology (Northwood, London, England) · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Manoj Kumar SinghDepartment of Laboratory Medicine, School of Tropical Medicine, 108, C.R. Avenue, Kolkata, 700073, West Bengal, India.
Debanjan Bhattacharya
Suhnrita Chaudhuri
Sagar Acharya
Pankaj Kumar
Pranjal Santra
Anjan Kumar Basu
Swapna Chaudhuri
KPC Medical College and Hospital · INVidyasagar University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During glioma development, angiogenesis plays a crucial role in growth and vascularization of primary brain tumors. T11 target structure (T11TS), a bioactive molecule, has been documented as an anti-neoplastic agent in glioma-induced rats and also in human glioma in vitro. This novel molecule induces apoptosis of tumor cells by way of immune potentiation and impairs the glioma cell cycle, but its role in glioma angiogenesis has not been worked out in detail. Matrix metalloproteinases (MMPs) are enzymes promoting tumor angiogenesis by enzymatically remodeling the extracellular matrix and altering surface protein expression such as integrin αv and the matrix-bound proteins like TGF-β1. The present study was formulated to assess the efficacy of T11TS in the modulations of MMP-2 and -9 and their endogenous inhibitors (TIMP-1 and TIMP-2) as well as modulations of integrin αv and TGF-β1 in glioma-induced rats and also on the phenotypic markers of endothelial cells (CD31 and CD34). The parameters used were zymography, western blot, and flow cytometric analyses. It was observed that T11TS administration significantly downregulates the expression of matrix metalloproteinase-2 and -9 along with its ligand integrin αv and upregulates TIMP-1 and TIMP-2. In situ immunofluorescence and FACS results revealed that T11TS administration decreased the expression of the phenotypic markers (CD31/PECAM1, CD34), inhibiting the cell grip and also downregulating TGF-β1 expression (ELISA) from microglia cells in the glioma microenvironment. These results suggest that T11TS suppresses the expression of positive angiogenic growth factors and potentiates the expression of negative regulators in glioma-associated endothelial cells (ECs), resulting in an anti-angiogenic effect on glioma-induced angiogenesis.

Indexed as

Angiogenesis InhibitorsAnimalsBlotting, WesternEndothelial CellsFlow CytometryFluorescent Antibody TechniqueGliomaGlycopeptidesIntegrin alphaVMatrix MetalloproteinasesNeovascularization, PathologicRatsTissue Inhibitor of MetalloproteinasesTransforming Growth Factor beta1Angiogenesis InhibitorsGlycopeptidesIntegrin alphaVMatrix MetalloproteinasesTissue Inhibitor of MetalloproteinasesTransforming Growth Factor beta1

Identifiers

PMID24242015
OpenAlexW2034865262

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.